SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
Discover4568.T
HealthcareTSEJPY

Daiichi Sankyo

¥00123456789,001234567890012345678900123456789.0012345678900123456789+6.6%
52w low (est.) ¥2,346.56¥3,354.49 52w high (est.)
Peers
Market data
Market cap
¥4.97T
52-week range
¥2,390.00 – ¥4,178.00
Sector
Healthcare
Valuation
P/E ratio
19.5x
DCF fair value
¥1,192.98
Margin of safety
-56.9%
Forward P/E
19.0x
PEG ratio
1.79
Dividend yield
3.66%
Quality & efficiency
Moat score
78/100
Return on equity
15.8%
Profit margin
12.2%
Debt / equity
0.21
Growth & analysts
Revenue growth (YoY)
+13.7%
Analyst target
¥4,205.29
Target upside
+52.0%
Analysts covering
17

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.

Valuation

ValueGrowthProfitHealthIncome51QUALITY
Overall Rating
47
Hold
Hold
Moat Score78
DCF Intrinsic Value
¥1,192.98-56.9% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
¥4.97T
P/E Ratio
19.5
Dividend Yield
3.66%
Revenue Growth
+13.7%
Profit Margin
12.2%
ROE
15.8%
Debt / Equity
0.21
Beta
-0.16
Dividend Aristocrats
vs Healthcare sector:P/E 19 vs 28 · cheaperMoat 78 vs 7Yield 3.66% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · 4568.T